Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic, Autoimmune, and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for H4C9 drug discovery and epigenetic research. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Histone H4 (Canonical sequence identical to H4C9) High purity (>95% by SDS-PAGE), Endotoxin <1.0 EU/µg. Sequence Verified. Suitable for nucleosome assembly and transferase assays. |
View H4C9 Products |
| Gene Delivery | H4C9 Promise-ORF / Lentivirus Full-length ORF clone for stable overexpression. Specifically sequence-verified for the H4C9 gene locus (formerly HIST1H4I) to study transcriptional regulation. |
View H4C9 Products |
| Benchmark Ab | Anti-Histone H4 / Modified Histone H4 Antibodies Recombinant positive control antibodies targeting total Histone H4 or specific post-translational modifications (e.g., Acetylation/Methylation). |
View H4C9 Products |
| Validator | H4C9 siRNA Set Specifically designed to target the unique 3' UTR or 5' UTR of the H4C9 transcript, enabling gene-specific knockdown without cross-reacting with other highly conserved histone H4 paralogs. |
View H4C9 Products |
| Related Target A | HAT1 Histone Acetyltransferase 1, the primary enzyme responsible for cytoplasmic acetylation of newly synthesized histone H4. |
View HAT1 Products |
| Related Target B | HDAC1 Histone Deacetylase 1, a key epigenetic eraser regulating histone H4 deacetylation and chromatin condensation. |
View HDAC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Histone H4 Paralog Differentiation Amino acid sequences of canonical histone H4 proteins (including H4C9, H4C1, etc.) are identical, preventing protein-level differentiation. |
Locus-Specific Genetic Tools: Sequence-verified H4C9 ORF clones and UTR-specific siRNA sets designed to target unique non-coding regions, ensuring transcript-level specificity. |
| Post-Translational Modification (PTM) Screening Evaluating enzymes (HATs, HDACs, HMTs) requires unmodified, highly pure substrate. |
High-Purity Recombinant Standards: Unmodified recombinant Histone H4 proteins expressed in systems ensuring the absence of eukaryotic background modifications, verified by Mass Spectrometry. |
| Lack of Assay Controls Inconsistent baseline readings in nucleosome assembly or antibody binding assays. |
Clinical Benchmark Biosimilars: Recombinant positive control antibodies and validated reference materials included in every batch. |
| Off-Target Genetic Knockdown Standard siRNAs often cross-react with other histone H4 genes due to high coding sequence homology. |
UTR-Targeted siRNA Design: Custom-designed siRNA pools targeting the divergent untranslated regions unique to the H4C9 transcript. |
Live H4C9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of chromatin architecture is undergoing a significant transition. While direct targeting of the highly conserved Histone H4 protein (such as the product of the H4C9 gene) is challenging due to sequence identity across canonical H4 paralogs, the focus has shifted toward modulating the writer, reader, and eraser enzymes that act upon its N-terminal tail. Additionally, extracellular Histone H4 has emerged as a major mediator of tissue damage in sepsis and autoimmune diseases, prompting the development of neutralizing antibodies.
The next wave of R&D is focusing on locus-specific transcriptional regulation (using CRISPR-dCas9 tools targeted to the H4C9 genomic locus) and the development of highly selective small molecule inhibitors against histone-modifying complexes (e.g., HATs, HDACs, and methyltransferases) to correct epigenetic dysregulation in hematological and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (Epigenetic) | Incyte, Bristol Myers Squibb, Novartis | T-cell Lymphoma, Myelofibrosis, Solid Tumors | Enzymatic Activity Assays (Requires unmodified recombinant Histone H4 substrate) |
| Neutralizing Antibodies (Extracellular) | Academic Medical Centers, Biotech Startups | Sepsis, Autoimmune Diseases (e.g., SLE), Thrombosis | Binding Affinity & Neutralization Assays (Requires endotoxin-controlled recombinant Histone H4) |
| RNA Interference / CRISPR | Alnylam, Intellia Therapeutics | Genetic Epigenetic Disorders, Refractory Cancers | Locus-Specific Validation (Requires UTR-specific H4C9 siRNA and sequence-verified ORF clones) |